Retrospective analysis shows outpatient blinatumomab reduces hospitalization and toxicity in B-ALL patients, suggesting a safe treatment pathway.
Key Points
Outpatient administration of blinatumomab resulted in lower rates of hospitalization compared to inpatient care, supporting better patient management.
C1 outpatient patients had a significantly lower rate of cytokine release syndrome versus inpatient patients, indicating potential safety benefits.
Retrospective cohort study assessed treatment outcomes of multiple centers, contributing valuable real-world data on blinatumomab use.
Lower median days of hospitalization for outpatient blinatumomab initiation in Cycle 2 emphasizes the importance of healthcare utilization optimization.